CO based therapies

The first reported transition metal-based CORM (tmCORM) was the commercial dimer [Ru(CO)3Cl2]2 (CORM-2 Figure 6.1) [21]. The broad range of biological and therapeutic data presented in Section 6.3 mimics CO gas and HO-1 induction, suggesting for the first time that CO-based therapy was possible with transition metal CORMs. 

Romao, C.C. and Vieira, H.LA. (2013) Metal carbonyls for CO-based therapies challenges and successes, in Advances in Organometallic Chemistry and Catalysis The Silver/Gold Jubilee International Conference on Organometallic Chemistry Celebratory Book (ed. A. Pombeiro), John Wiley Sons, Inc., Hoboken, NJ. 

METAL CARBONYLS FOR CO-BASED THERAPIES CHALLENGES AND SUCCESSES... 

In 330 HIV-positive, of whom 267 received nevirapine-based antiretroviral therapy and 63 received efavirdine-based therapy there was a significant difference in the rates of hepatotoxicity 133 (50%) of the patients on nevirapine had at least one episode of a rise on alanine aminotransferase activity over a median follow-up period of 21 months, or 285 cases per 1000 person-years [96 ]. A baseline rise in activity (OR = 14) and hepatitis C co-infection (OR=3) were susceptibility factors, and a high CD4-I- cell count was protective. 

Presently, 1,260 gene-therapy trials are underway worldwide (Tables 1 and 2). For details see http // www.wiley.co.uk/genetherapy/clinical/. Almost three fourths of all trials are based on viral vectors. The vast majority of nonviral gene-therapy trials use naked/ plasmid DNA (18% of all gene-therapy trials). 

Figure 14.2 Vectors used thus far in gene therapy trials. Others are mainly viral-based and include the use of pox, vaccinia and adeno-associated viruses, as well as herpes simplex virus. Data adapted from www.wiley. co.uk/genemed/clinical...

Section 1 of the guidelines establishes the context of the submission. It asks for a description of the drug, its use on the PBS and the therapies that wiU be co-administered or substituted. Section 2 asks for the best available evidence on the clinical performance of the drug, including the scientific and statistical rigour of randomised trials, and a preliminary economic evaluation based on evidence from the randomised trials. Section 3 describes when extrapolation beyond the preliminary economic evaluation maybe made and how adjustments can be made in a modelled economic evaluation. Section 4 requests a financial analysis from the perspective of the PBS and government health budgets. 

Gene expression inhibition. Chloroform/ methanol extract (1 1) of the dried leaf, in cell culture, was active on hepatoma-Cos-7, IC50 600.0 pg/mL vs TAT-dependent activation of HIV promoter hioassay - . Hepatotoxic activity. The leaf, taken orally by a female adult, was active - . A patient consumed 15 tablets of the leaf per day for 4 months. Approximately 1 year after stopping consumption, liver enzymes returned to normal and fatigue was no longer a complaint - ". Infusion of the dried leaf, taken orally by a female adult at variable doses, was active. The 60-year-old woman who took Lama tridentata for 10 months developed severe hepatitis for which no other cause could be found. Despite aggressive supportive therapy, the patient s condition deteriorated and required orthotropic liver transplantation - " . Dried leaves, administered orally to adults at variable doses, were active. A public warning has been issued by the US Centers for Disease Control based on reports of liver toxicity after use of Lama tridentata tea - " k Dried leaves, administered orally to adults of both sexes at variable doses, were active - ". The plant, administered orally to adults at variable doses, was active - ". Dried leaves, administered orally to adults at variable doses, were active. One case of hepatotoxicity induced by Larrea tridentata taken as a nutritional supplement was reported - ". Thirteen patients were identified for whom Larrea tridentata tincture for internal use was prescribed. Additionally, 20 female and three male patients were identified from whom an extract of Larrea tridentata in castor oil for... 

The possible impact of co-administered chemotherapies and radiation therapy on the PK of cetuximab was furthermore assessed using the population PK approach, as described in Section 14.6. The co-administered chemotherapies included cisplatin, carboplatin, paclitaxel, doxorubicin, irinotecan, and gemcitabine. The results of the analysis indicate that neither the co-administered chemotherapies nor radiation therapy had a significant impact on the PK of cetuximab. This finding suggests that the potential for PK-based drug-drug interactions with cetuximab is low. 

---